As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

The Dow, S&P 500, and Nasdaq fell Thursday as the stock market digested the latest economic data and Trump's response to Canada and EU tariffs. The S&P 500 closed in correction territory.

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat ...

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...